Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Non-Current Assets (2018 - 2025)

10x Genomics (TXG) has disclosed Non-Current Assets for 8 consecutive years, with $356.9 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 6.78% to $356.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 billion through Dec 2025, down 0.87% year-over-year, with the annual reading at $356.9 million for FY2025, 6.78% up from the prior year.
  • Non-Current Assets hit $356.9 million in Q4 2025 for 10x Genomics, down from $367.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $412.1 million in Q1 2023 to a low of $208.3 million in Q1 2021.
  • Historically, Non-Current Assets has averaged $334.0 million across 5 years, with a median of $347.2 million in 2024.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 75.02% in 2021 and later decreased 13.81% in 2024.
  • Year by year, Non-Current Assets stood at $271.2 million in 2021, then soared by 45.24% to $393.9 million in 2022, then dropped by 6.3% to $369.1 million in 2023, then dropped by 9.45% to $334.2 million in 2024, then increased by 6.78% to $356.9 million in 2025.
  • Business Quant data shows Non-Current Assets for TXG at $356.9 million in Q4 2025, $367.5 million in Q3 2025, and $324.3 million in Q2 2025.